Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial.
Identifieur interne : 000171 ( Main/Exploration ); précédent : 000170; suivant : 000172Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial.
Auteurs : Brenda L. Coleman [Canada] ; Shaza A. Fadel ; Steven J. Drews ; Todd F. Hatchette ; Allison J. McgeerSource :
- Influenza and other respiratory viruses [ 1750-2659 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Antiviraux, Vaccins antigrippaux, Zanamivir.
- Adulte, Adulte d'âge moyen, Canada, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Projets pilotes, Saisons, Tests d'inhibition de l'hémagglutination.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Antiviral Agents, Influenza Vaccines, Zanamivir.
- geographic : Canada.
- prevention & control : Influenza, Human.
- Adult, Female, Hemagglutination Inhibition Tests, Humans, Male, Middle Aged, Pilot Projects, Seasons, Young Adult.
Abstract
BACKGROUND
Healthcare workers may be exposed to people with respiratory viral infections more often than other working adults. Understanding the risk and the effectiveness of different preventive measures is of great importance.
OBJECTIVES
To estimate adherence to prophylactic antiviral medication for a full influenza season, to the compare efficacy of antiviral prophylaxis to that of the seasonal influenza vaccine and to identify exposures that increase risk of acute respiratory illnesses (ARI) in healthy adults.
METHODS
Participants were randomized 1:2 to receive the 2008-2009 influenza vaccine or daily prophylaxis with 10 mg of zanamivir during the season. Web-based questionnaires collected information on demographics, symptoms, exposures, medication use and side effects.
RESULTS
Sixty-four healthy adults were recruited in November 2008. Three of 40 active participants discontinued zanamivir due to side effects; the remaining 37 took >85% of scheduled doses for a median of 121 days. Symptomatic, laboratory-confirmed influenza was detected in one person randomized to zanamivir (2·5%) and 2/20 (10%) who received the vaccine (P = 0·25). Forty-seven participants reported 109 episodes of ARI. Factors associated with an ARI were exposure to a spouse (OR 7·2), child (OR 2·4) or patient (OR 2·0) with symptoms of an ARI in the previous 7 days.
CONCLUSIONS
Breakthrough influenza infection occurred in both vaccinated participants and those receiving antiviral prophylaxis. Most adults were willing and able to comply with season-long prophylaxis. Report of recent exposure to family members and patients with an ARI increased the risk of developing an ARI in healthy adults.
DOI: 10.1111/irv.12301
PubMed: 25557838
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial.</title><author><name sortKey="Coleman, Brenda L" sort="Coleman, Brenda L" uniqKey="Coleman B" first="Brenda L" last="Coleman">Brenda L. Coleman</name><affiliation wicri:level="4"><nlm:affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Department of Microbiology, Mount Sinai Hospital, Toronto, ON</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Fadel, Shaza A" sort="Fadel, Shaza A" uniqKey="Fadel S" first="Shaza A" last="Fadel">Shaza A. Fadel</name></author><author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name></author><author><name sortKey="Hatchette, Todd F" sort="Hatchette, Todd F" uniqKey="Hatchette T" first="Todd F" last="Hatchette">Todd F. Hatchette</name></author><author><name sortKey="Mcgeer, Allison J" sort="Mcgeer, Allison J" uniqKey="Mcgeer A" first="Allison J" last="Mcgeer">Allison J. Mcgeer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25557838</idno><idno type="pmid">25557838</idno><idno type="doi">10.1111/irv.12301</idno><idno type="wicri:Area/Main/Corpus">000232</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000232</idno><idno type="wicri:Area/Main/Curation">000232</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000232</idno><idno type="wicri:Area/Main/Exploration">000232</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial.</title><author><name sortKey="Coleman, Brenda L" sort="Coleman, Brenda L" uniqKey="Coleman B" first="Brenda L" last="Coleman">Brenda L. Coleman</name><affiliation wicri:level="4"><nlm:affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Department of Microbiology, Mount Sinai Hospital, Toronto, ON</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Fadel, Shaza A" sort="Fadel, Shaza A" uniqKey="Fadel S" first="Shaza A" last="Fadel">Shaza A. Fadel</name></author><author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name></author><author><name sortKey="Hatchette, Todd F" sort="Hatchette, Todd F" uniqKey="Hatchette T" first="Todd F" last="Hatchette">Todd F. Hatchette</name></author><author><name sortKey="Mcgeer, Allison J" sort="Mcgeer, Allison J" uniqKey="Mcgeer A" first="Allison J" last="Mcgeer">Allison J. Mcgeer</name></author></analytic><series><title level="j">Influenza and other respiratory viruses</title><idno type="eISSN">1750-2659</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiviral Agents (administration & dosage)</term><term>Canada</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Seasons</term><term>Young Adult</term><term>Zanamivir (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (administration et posologie)</term><term>Canada</term><term>Femelle</term><term>Grippe humaine ()</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Projets pilotes</term><term>Saisons</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Zanamivir (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Influenza Vaccines</term><term>Zanamivir</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Vaccins antigrippaux</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Seasons</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Canada</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Projets pilotes</term><term>Saisons</term><term>Tests d'inhibition de l'hémagglutination</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Healthcare workers may be exposed to people with respiratory viral infections more often than other working adults. Understanding the risk and the effectiveness of different preventive measures is of great importance.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To estimate adherence to prophylactic antiviral medication for a full influenza season, to the compare efficacy of antiviral prophylaxis to that of the seasonal influenza vaccine and to identify exposures that increase risk of acute respiratory illnesses (ARI) in healthy adults.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Participants were randomized 1:2 to receive the 2008-2009 influenza vaccine or daily prophylaxis with 10 mg of zanamivir during the season. Web-based questionnaires collected information on demographics, symptoms, exposures, medication use and side effects.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Sixty-four healthy adults were recruited in November 2008. Three of 40 active participants discontinued zanamivir due to side effects; the remaining 37 took >85% of scheduled doses for a median of 121 days. Symptomatic, laboratory-confirmed influenza was detected in one person randomized to zanamivir (2·5%) and 2/20 (10%) who received the vaccine (P = 0·25). Forty-seven participants reported 109 episodes of ARI. Factors associated with an ARI were exposure to a spouse (OR 7·2), child (OR 2·4) or patient (OR 2·0) with symptoms of an ARI in the previous 7 days.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Breakthrough influenza infection occurred in both vaccinated participants and those receiving antiviral prophylaxis. Most adults were willing and able to comply with season-long prophylaxis. Report of recent exposure to family members and patients with an ARI increased the risk of developing an ARI in healthy adults.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25557838</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial.</ArticleTitle><Pagination><MedlinePgn>78-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.12301</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Healthcare workers may be exposed to people with respiratory viral infections more often than other working adults. Understanding the risk and the effectiveness of different preventive measures is of great importance.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To estimate adherence to prophylactic antiviral medication for a full influenza season, to the compare efficacy of antiviral prophylaxis to that of the seasonal influenza vaccine and to identify exposures that increase risk of acute respiratory illnesses (ARI) in healthy adults.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants were randomized 1:2 to receive the 2008-2009 influenza vaccine or daily prophylaxis with 10 mg of zanamivir during the season. Web-based questionnaires collected information on demographics, symptoms, exposures, medication use and side effects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-four healthy adults were recruited in November 2008. Three of 40 active participants discontinued zanamivir due to side effects; the remaining 37 took >85% of scheduled doses for a median of 121 days. Symptomatic, laboratory-confirmed influenza was detected in one person randomized to zanamivir (2·5%) and 2/20 (10%) who received the vaccine (P = 0·25). Forty-seven participants reported 109 episodes of ARI. Factors associated with an ARI were exposure to a spouse (OR 7·2), child (OR 2·4) or patient (OR 2·0) with symptoms of an ARI in the previous 7 days.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Breakthrough influenza infection occurred in both vaccinated participants and those receiving antiviral prophylaxis. Most adults were willing and able to comply with season-long prophylaxis. Report of recent exposure to family members and patients with an ARI increased the risk of developing an ARI in healthy adults.</AbstractText><CopyrightInformation>© 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Brenda L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fadel</LastName><ForeName>Shaza A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Drews</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Hatchette</LastName><ForeName>Todd F</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>Allison J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">respiratory tract infections</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25557838</ArticleId><ArticleId IdType="doi">10.1111/irv.12301</ArticleId><ArticleId IdType="pmc">PMC4353320</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Influenza Other Respir Viruses. 2015 Mar;9(2):78-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25557838</ArticleId></ArticleIdList></Reference><Reference><Citation>Perspect Clin Res. 2011 Jul;2(3):109-12</Citation><ArticleIdList><ArticleId IdType="pubmed">21897887</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2010 Jan 12;10:8</Citation><ArticleIdList><ArticleId IdType="pubmed">20067628</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2007 Aug;29(8):1579-90; discussion 1577-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17919541</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Jul 7;282(1):31-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10404908</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2008 Jul;34(7):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18802987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2011 Nov;5(6):404-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21668681</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Allergy Asthma Rep. 2014 Feb;14(2):413</Citation><ArticleIdList><ArticleId IdType="pubmed">24415465</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Nurs. 2008 Nov-Dec;25(6):565-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18950421</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Oct 28;341(18):1336-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10536125</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2011 Jun;17(6):1000-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21749760</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Recomm Rep. 2011 Nov 25;60(RR-7):1-45</Citation><ArticleIdList><ArticleId IdType="pubmed">22108587</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2008 Jul;34(ACS-3):1-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18802991</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(6):e21335</Citation><ArticleIdList><ArticleId IdType="pubmed">21731708</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2012 Oct 1;206(7):1078-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22837493</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(10):e26239</Citation><ArticleIdList><ArticleId IdType="pubmed">22028840</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2013 Apr;19(4):606-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23631831</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name><name sortKey="Fadel, Shaza A" sort="Fadel, Shaza A" uniqKey="Fadel S" first="Shaza A" last="Fadel">Shaza A. Fadel</name><name sortKey="Hatchette, Todd F" sort="Hatchette, Todd F" uniqKey="Hatchette T" first="Todd F" last="Hatchette">Todd F. Hatchette</name><name sortKey="Mcgeer, Allison J" sort="Mcgeer, Allison J" uniqKey="Mcgeer A" first="Allison J" last="Mcgeer">Allison J. Mcgeer</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Coleman, Brenda L" sort="Coleman, Brenda L" uniqKey="Coleman B" first="Brenda L" last="Coleman">Brenda L. Coleman</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000171 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000171 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25557838
|texte= Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25557838" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |